Telemundo Houston to Air Special on Immigration
Telemundo Houston (KTMD) is airing a one-hour special edition of Noticias Telemundo Houston called Mesa De Análisis, Inmigración Y Tus Derechos today at 4 p.m. CT.
The show is the third installment of an immigration forum and is part of the broader Inmigración y Tus Derechos initiative led by Telemundo-owned stations. The initiative includes special reports, local town halls, and community events designed to educate, inform, and empower viewers with accurate and timely information about immigration rights and resources.
Anchored by Telemundo Houston's Crystal Ayala and Ingrid Barrera, the special brings together top immigration experts and community leaders to discuss recent developments in immigration law and policy and what they mean for the local community members. Panelists include: Immigration attorneys Naimeh Salem and Silvia Mintz, Beatriz Trillos, the Chair, American Immigration Lawyers Association – Texas Chapter, David Donatti, Senior Attorney, ACLU of Texas, Teodoro Aguiluz, President, CRECEN, César Espinoza, Executive Director, FIEL Houston.
The panel will discuss a variety of topics, including deportation to third countries, enforcement of the Alien Enemies Act, immigrant registration, and judicial challenges to immigration policies. Experts will also examine how recent executive orders are affecting the lives of immigrants, such as access to mortgage loans, legal aid for children, and increased data sharing among government agencies, as well as growing concerns around local police cooperation with immigration authorities, visa revocations for students, teachers, and tourists, and the loss of both permanent and temporary legal status in the U.S.
The special will also air on several Telemundo-owned stations, including Telemundo 40 Rio Grande Valley, Telemundo 60 San Antonio, Telemundo 48 El Paso, Telemundo Nuevo México, Telemundo Colorado, Telemundo Nueva Inglaterra, Telemundo Utah, Telemundo Fresno and Telemundo 33 Sacramento. Check local listings for air dates and times.
It will simulcast on Noticias Telemundo Texas, the free, ad-supported streaming TV (FAST) regional news channel.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
TikTok creating more than 500 new British jobs as UK users top 30 million
TikTok creating more than 500 new British jobs as UK users top 30 million TikTok has unveiled plans to create more than 500 new British jobs and open a second office in London as it cheered passing the 30 million milestone for users in the UK. The Chinese-owned social media firm said its UK workforce would expand to 3,000 this year as part of its 'deep commitment' to the UK. It will also open a new 135,000sq ft office in London's Barbican, which is set to open early next year. The group already has its UK headquarters in Farringdon, London, which were opened in 2022. TikTok unveiled the plans as it said it now has more than 30 million regular users in the UK each month, which makes the market is biggest user community in Europe. ADVERTISEMENT Adam Presser, director of TikTok UK and global head of operations and trust and safety, said: 'Whether through direct investment in jobs and innovation, or the wider economic contribution from millions of British businesses on TikTok, we're pleased to be increasing our investment and presence here in the UK, an important hub for TikTok.' But it comes after Cabinet minister Pete Kyle signalled he was looking at measures to restrict the amount of time children spend on their phones, including through a possible 10pm curfew. Mr Kyle was asked on Sunday morning whether he would look at limiting the time children spend on social media to two hours per app after the Sunday People and Mirror reported the measure was being considered by ministers. The Online Safety Act has passed into law, and from this year will require tech platforms to follow new Ofcom-issued codes of practice to keep users safe online, particularly children. Hefty fines and site blockages are among the penalties for those caught breaking the rules, but many critics have argued the approach gives tech firms too much scope to regulate themselves. ADVERTISEMENT TikTok's Mr Presser said that, as well as its UK expansion plans, the group also invests 'significantly' in safety. The firm launched its UK operations in 2018 (James Manning/PA) He said: 'What underpins our continued growth is our deep commitment to safety and to creating an enjoyable and secure digital space to sustainably support creators, entrepreneurs and the wider economy, which is why we also invest significantly in safety.' TikTok first launched its UK operations in 2018 and is financially incorporated in Britain. The group was fined 530 million euro (£446 million) by the Irish data protection watchdog last month for breaching EU privacy rules around transferring user data to China. The video-sharing app was also sanctioned for not being transparent with users about where personal data was being sent and ordered the platform to comply with data protection rules within six months. ADVERTISEMENT TikTok said it would appeal against the decision. The social media giant, which is owned by China-based ByteDance, has been under scrutiny from regulators around the world over how it handles personal data, and is also facing a ban in the United States over its China links, which the US government has said is a national security issue.
CNBC
5 hours ago
- CNBC
Investors assess their U.S. exposure as uncertainty creates concerns — and opportunities
As investors assess whether the U.S. is still a good place to put their money, the list of events in the country making global headlines just keeps growing. Front of mind for investors is both U.S. President Donald Trump's tariffs regime — with much anticipated talks between the U.S. and China taking place in London on Monday — and the spending bill , which could allow the U.S. to add a new tax of up to 20% on foreigners with U.S. investments. Indeed, the market volatility under Trump's presidency so far has led some investors to diversify to other markets to ride it out. BofA fund flows data has shown investors fleeing U.S. equities and piling into Europe and Japan this year. "Policy uncertainty has risen in recent months, both globally and particularly in the U.S., and we think that will continue to inform debates among investors about the right exposure to U.S. assets," Richard Flax, chief investment officer at Allianz-owned Moneyfarm, told CNBC Monday. Over the weekend, riots in LA became the latest news to make headlines around the world as protesters demonstrating against federal immigration raids clashed with law enforcement . Investors said that no immediate market impact was expected from the ongoing riots, but they would be watching the Trump administration's response closely. "The riots themselves, I don't think are going to make things any worse — unless, of course, this goes on for another couple of weeks, or it spreads to other cities in the U.S.," Rami Cassis, founder of family office Parabellum Investments, told CNBC Monday in a phone call. "It's something we've seen in LA before, and I think most investors will see it just as that and hope that things settle down. The administration's response, on the other hand, means that they're a little bit more under the microscope, and how they address this is going to be telling." As the unrest continued, U.S. President Donald Trump deployed the National Guard to the city , federalizing part of California's National Guard that would ordinarily be under the control of state governor Gavin Newsom — who lashed out at the White House's response to the unrest. Meanwhile, U.S. Defense Secretary Pete Hegseth said on social media that U.S. Marines were "on high alert" and would be mobilized if violence continued in the city. Cassis added that the Trump administration's reaction to the LA protests so far "don't reflect well on an administration looking to resolve this in a sensible way." "I think the other concern is Trump's position on legal and illegal immigration, I think, is likely to eventually be a risk for the U.S. economy in terms of how its workforce is made up and access to resources," Cassis said. 'Surprisingly resilient' U.S. market Iain Barnes, chief investment officer at London-based wealth manager Netwealth, agreed that the response to the riots, rather than the event itself, was likely to strike a chord with investors who had already had their confidence in the U.S. shaken . "Taken on their own, we don't see the images of police and national guard on streets in LA as a signal for investors' views on the U.S. to change, but it does keep U.S. politics in market focus and will give global investors another excuse to say that the outlook for the world's biggest stock market has deteriorated," he explained. "The socially conservative standpoint on issues like immigration was expected, so it's the economic policies that have dented the confidence of domestic and international investors so far." Despite this, Barnes noted on Monday that nearly six months into Trump's second term, the U.S. market continued to look "surprisingly resilient given what's been thrown at it." Despite volatility, the S & P 500 index is still over 12% higher over the last 12 months. .SPX YTD mountain S & P 500 "Profit margins are at historically strong levels, spurring a strong rebound since the Liberation Day-induced panic so valuations remain our primary concern here," he said. "Heat has come out of the labor market and inflation is also cooling for now." He added that some areas of the U.S. actually looked ripe for investment. "We think the real yields on offer from U.S. Treasuries are increasingly attractive, should the growth profile deteriorate once the 90-day pause on Trump's 'reciprocal' tariff rates expires in early July," he said. "We still expect passive diversification away from U.S. assets over the medium term, but on a more cyclical view U.S. dollar weakness is likely to slow, if not revert." Pivot to Europe? Speaking on CNBC's "Europe Early Edition" Monday, John Blank, chief equity strategist at Zacks Investment Research, said broad diversification away from the U.S. was unlikely to end any time soon. "There's a regime shift away from the Trump administration, and the Trump administration's going to be with us — at least in this form, [with] control of both houses — for another 18 months. So it's very hard to say that people are going to change the thematic around avoiding a dominant Trump country, the United States, any time soon," he said. Europe was currently a good alternative to the U.S. for investors, Blank argued. "I think the fundamentals of the infrastructure packages , the defense packages , and the open arms Europe has shown for the Middle East and Canada and China, all of that's going to track interest in Europe in a way that we haven't seen in a while," he told CNBC. "Given how this president likes to not only tear up but put down immigration, put down international students, I cannot imagine anything but that creating a relative bid for European equities and European investment in a more direct sense as well."
Miami Herald
8 hours ago
- Miami Herald
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline 83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS) 9.1 point average rVCSS improvement among the clinically meaningful benefit cohort Subjects experienced a median 74% improvement in leg pain Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025 Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below). Key interim two-year follow-up data being presented at VAM25 include: 83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate. All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases. "These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option." Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025. The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025. Webcast Details The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, and will be archived for 90 days. About CVI Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year. About enVVeno Medical Corporation enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe. Cautionary Note on Forward-Looking Statements This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law. INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@ 824-0775 MEDIA CONTACT:Glenn Silver, FINN 818-8198 SOURCE: enVVeno Medical Corporation
